
Detroit Zoo celebrates World Penguin Day with wild penguin conservation work
Since 2013, the Detroit Zoo has partnered with Falklands Conservation, a nature organization based in the Falkland Islands that monitors seabird and other wildlife populations. As part of their seabird program, Detroit Zoo staff helped count the number of penguins around the region. Staff traveled to various, far-flung islands. Drones were purchased so that workers could do aerial surveys and count that way, saving great time and effort.
During that partnership, Falkland Conservation noticed alarming population declines.
'All seabird populations are declining,' said Ann Duncan, Associate Vice President of Life Sciences for the Detroit Zoological Society (DZS). 'The animals that are near to the polar areas of the world are being affected quite a bit by climate change, so they were concerned about the things that might be causing these decreases – particularly the impact petroleum activity in the area might have.'
The DZS' bird curator at the time reached out to the animal health team, led by Duncan. In order to create a study that would explore those impacts, Duncan led a small team to the Falklands in 2018, 2019 and 2024, going each time in autumn, which is nesting season. Blood samples and toxicology testing were done to look for evidence of an immune symptom response to various diseases, a process called serology.
'We also look for the pathogens themselves,' said Duncan, 'using PCR and looking for the DNA of the types of pathogens that we think would impact penguins in the wild. It's a big effort. Traveling to the Falklands is challenging; it takes over two days to get there, and we ship our supplies ahead of time. We have to keep the samples cold when we transport them back from the Falklands, so we travel with a great, big dry shipping liquid nitrogen tank that maintains a really cold temperature inside and keeps the samples preserved.'
Duncan said the exploration of the samples is ongoing.
'What we do know,' she said, 'is that high path avian influenza is a global concern and has had an impact on some marine mammals in the area north of the Falklands, so we're taking a closer look at that. We see evidence of other diseases, but for the most part, the penguins that we've looked at have been healthy, and that's a good thing to see.
'However, there had been one site where we generally sample the penguins, that the landowner had noticed the number of rock hopper penguins in that colony had decreased by a lot. They didn't want us to go into that colony to collect samples, because they're concerned. There are some areas where the flock sizes are still good, and other areas where the flock sizes are not good, so this kind of work, looking at what's impacting these animals, is important to understanding them.'
One thing the study allowed them to do was compare and contrast samples from penguins that were far away from humans and petroleum with populations that were closer to those influences.
'There are so many pressures on wild populations,' said Duncan. 'Some of them are climate, some of them are man-made things like the petroleum industry in the area. One of the reasons why Falklands Conservation wanted to partner with us is because it may be possible to learn if there are certain contaminants in the environment, and measures that could be taken to change things, or policies that could be written that could change the way things are done. If they could prove that there was an impact coming from petroleum shipping or from oil spills or other things going on in the area, they might be able to influence and avoid some of those things moving forward. That's the ultimate goal.'
See also: Detroit's Hannan Center called 'one of Michigan's best-kept secrets' for senior citizens
Duncan emphasized that science is important, and that every citizen is capable of helping with conservation.
'Science is real,' she said. 'It is evidence-based. It's performed by scientists who are trained, and it can spark and ignite an interest in the people who live in the Detroit area, understanding more about the ways that animal populations are being impacted globally, and looking for ways that they can make a difference. And that can be financial support to an organization that's doing work. It can be just learning more and talking about it, and igniting that spark in other people. It can be visiting the zoo, because when you visit the zoo, your financial support of admission does go toward our conservation programs. That's partly how we fund this.
'And it can be voting. It can be getting active and influencing legislation here in the United States that impacts things like climate change, impacts things like clean water, impacts things that are affecting wildlife everywhere, including in Michigan, in our area, in our footprint. All of those things are interwoven.'
David Dimitrie, DZS Director of Conservation, said the work being done here at the Detroit Zoo results in the zoo being able to help animals in the wild.
'By having our animals at the Detroit Zoo,' he said, 'and having our team who are managing them and handling them and taking care of them day in and day out, and having Dr. Ann's team, with their knowledge, we are able to really provide an important health benefit to our partners in the field, and that expertise that I think can help leverage and elevate the conservation work that it happening.
'And so, what we're doing at the Zoo is allowing us to then go out into the field and also help with these important conversation projects. It's really exciting to have the animals here at the zoo, but also to have those skill sets that we can bring back out into the field.'
Duncan agreed.
'There's actually a viral disease that is to some extent impacting cat populations in managed care at other zoos and aquariums right now,' she said. 'One of the things we're going to do is test the animals in the wild to understand if this is also impacting wild penguins. That work can also help us inform the care of our animals that live here at the Detroit Zoo, so it does go both ways.'
Dimitrie emphasized that the Zoo is proud to be able to add support to projects like this.
'We have a really important skill set and a suite of scientific expertise,' said Dimitrie. 'We have Dr. Ann and her team from the vet and the health side of things. We have our bird team going down as well, and we have our penguins here at the Detroit Zoo. But we're also really focused on their conservation in the field, as well. That baseline data can really help us begin to untangle these different potential threats that the wildlife are facing down in the Falklands.
'But, at the same time, I think one of our roles is to always be thinking and looking ahead to the future and to the next potential conservation challenge that's going to be facing these habitats and these animals down there. Having this relationship and this work already established there can really help us be champions and leaders for helping to guide what the future of conservation may look like.'
To learn more or support the Detroit Zoo's conservation efforts, visit detroitzoo.com. To learn more about Falklands Conservation, visit falklandsconservation.com.
Contact Free Press arts and culture reporter Duante Beddingfield at dbeddingfield@freepress.com.
This article originally appeared on Detroit Free Press: Detroit Zoo celebrates World Penguin Day with conservation work

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Los Angeles Times
30-06-2025
- Los Angeles Times
‘Jurassic World Rebirth' is a cold-blooded clone in which wonder has gone extinct
Hold on to your water glasses because you can hear the plot of 'Jurassic World Rebirth' coming from a mile away. A ragtag group of adventurers land on a remote island planning to exploit dinosaur DNA — and some of them get chomped. The only new thing about this seventh installment is the cast: Scarlett Johansson and Mahershala Ali as freelance covert operatives Zora and Duncan, Jonathan Bailey as paleontologist Henry Loomis and Rupert Friend as a pharmaceutical titan named Martin who wants to treat coronary disease by harvesting samples from three massive reptile hearts. Gauging by the response every time this sequel has come up in conversation, it should have been subtitled: 'This Time There's No Chris Pratt.' I went to the theater with my own heart as big as a Titanosaur's. (Goofy name aside, it's a real herbivore and you'll see a herd of them.) After all, screenwriter David Koepp wrote the screenplay for the 1993 origina and the franchise's latest director, Gareth Edwards, made a serviceable 'Godzilla.' Alas, Edwards has made 'Godzilla' again. 'Jurassic World Rebirth' is a straight monster movie with zero awe or prestige. It's incurious about its stomping creatures and barely invested in the humans either, tasking Johansson and most of the cast to play fairly similar shades of hardy and determined. You'll see a nod to the 1962 adventure 'One Million Years B.C.' (you know: Raquel Welch, fur bikini), which is more of a template than a kitschy joke. There isn't a shiver of surprise about who gets the chomp, only disappointment that the fatalities are so bloodless — they're mild even for PG-13. Some of this ennui is by design. The narrative backdrop is that after 32 years of who-coulda-thunk-it rampages, humankind is tired of dealing with the darned things. Audiences can relate. To establish this miserliness of spirit, the present day scenes start with a Brooklyn traffic jam caused by an escaped sauropod laying collapsed and dying on the side of the road. It's the same species that transformed Sam Neill, Laura Dern and Jeff Goldblum into giddy, glassy-eyed children, only now drained of all majesty. Some creep has even spray-painted its hindquarters with graffiti. Plenty more dinosaurs will arrive in the film's two-hour-plus running time: swooping Quetzalcoatlus, splashing Mosasaurus, frilled Diophosaurus and a bitty Whoknowswhatasaurus that Ali's Duncan keeps in a bamboo birdcage by his boat dock in Suriname. But the only one that made me feel anything was that pathetic sauropod abandoned like a sidewalk sofa. A beat later, 'Rebirth' cuts to a shuttering museum exhibit where workmen are trashing their copy of that iconic banner that reads 'When dinosaurs ruled the earth.' The original 'Jurassic Park' inspired a generation of kids to dream of scientific discoveries. This era is throwing in the towel. The action sets sail with a hefty oceanic sequence where Edwards leans on his expertise in sluicing fins and underwater ka-thumps. Our heroes also scoop up a rather ungrateful shipwrecked family: yachtsman Reuben (Manuel Garcia-Rulfo), his daughters Isabella (Audrina Miranda) and Teresa (Luna Blaise) and Teresa's good-for-nothing boyfriend, Xavier (David Iacono). Initially, we can't wait for Iacono's louse to get eaten but we come to treasure his comic relief, particularly when Xavier wanders off to relieve himself next to a nest of velociraptors. Danger lurks and the doofus just stands around with his johnson in his hand. Eventually, the crew makes land on Ile Saint-Hubert near French Guinea, where a genetic dinosaur laboratory was evacuated 17 years earlier. In an opening flashback, we learn that a technician concocting a freakish T. rex littered a Snickers wrapper, causing a chain reaction that within two minutes resulted in the snacker becoming a snack. You may consider yourself inured to product placement. Even so, its use here is brazen and strange, from this case of death by chocolate to an 'E.T.' embezzlement in which Isabella befriends a baby Aquilops with red rope licorice. There's even a scene in an abandoned convenience store which, despite a decade and a half left in the custody of pesky dinosaurs, the snack labels remain tidily pointed toward the camera. At least that setting has a modifed raptor pausing at a soda cooler to admire its reflection. I don't think Johansson and Ali will take as much pride in 'Rebirth,' assuming they bother to watch it. Both get through the film without embarrassing themselves, in part because neither is very committed. Johansson's tough security expert swaggers, Ali smiles and our sturdy goodwill for both actors keeps us from holding the movie against them. Early on, the two get one scene together where they put on a pretense of speaking in shorthand about the emotional costs of a career in Blackwater-style skulduggery. It has the air of a stretch before buckling in for a long haul flight. This is composer Alexandre Desplat's 'Jurassic' debut and he dutifully reworks John Williams' famous notes of wonder and yearning a few ways, like a subtle tinkling when Bailey's strapping science geek imagines the joy of witnessing a dinosaur not in a zoo or a theme park, but in the wild. Bailey is a fine actor and his Loomis would be the soul of the movie if he wasn't battling for screen time. He's the only character who seems to like dinosaurs — everyone else sees them as dollar signs or boogeymen. The series itself has gotten so bored with the beasties that it continues to invent new ugly mutants. 'Rebirth' unleashes the Distortus rex — imagine a parakeet's head on a bodybuilding cockroach. All the dinos struggle to feel convincing as they seem to change size every time you look at them (and the CG backdrops are chintzy). Yet, I still prefer the trusty regulars like the amphibious Spinosaurs, who resemble dog-paddling hellhounds, the pecking Quetzalcoatlus that gulps people like sardines and, of course, the Tyrannosaurus rex, now striped and able to hide in ways that defy physics but at least get an audible chortle. 'Rebirth' is a confounding title for a downbeat entry that's mostly preoccupied by death and neglect. Who knows whether we're at the head or tail of the Anthropocene, but the movie seems weary of our dominion. 'I doubt if we make it to even 1 million,' Loomis admits, adding that he hopes to die in shallow silt so he can become a fossil too. With the franchise officially out of ideas, how about skipping to 'Jurassic Park: One Million Years A.D.' so a futuristic species can resurrect us for some malevolent fun and games?
Yahoo
03-06-2025
- Yahoo
Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference
ATLANTA, June 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) ('Dogwood' or the 'Company'), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced that CEO, Greg Duncan, will present a corporate overview at the Sidoti Small-Cap Virtual Conference being held on Wednesday, June 11, 2025 – Thursday, June 12, 2025. Presentation Date: Wednesday, June 11, 2025 Time: 9:15am Easter Time (Track 1) Webcast Link: Mr. Duncan will be available for one-on-one meetings. To request a meeting and to register for the conference, click here: About Dogwood Therapeutics Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Dogwood research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, NaV 1.7 analgesic program is centered on our lead development candidate, Halneuron®, which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain ('CINP'). Interim data from the ongoing Halneuron® Phase 2 CINP study are expected in Q4 of 2025. Dogwood's antiviral program includes IMC-1 and IMC-2, which are novel, proprietary, fixed-dose combinations of anti-herpes antivirals and the anti-inflammatory agent celecoxib. These combination antiviral approaches are being applied to the treatment of illnesses believed to be related to reactivation of previously dormant herpesviruses, including fibromyalgia ('FM') and Long-COVID ('LC'). IMC-1 is poised to progress into Phase 3 development as a treatment for FM and is the focus of external partnership activities. IMC-2 has been assessed in both active control and double-blind, placebo-controlled clinical trials and, in both cases, demonstrated successful reduction of the fatigue associated with LC. The company has reached an agreement with FDA on using reduction in fatigue as the primary endpoint for future LC research and is currently planning to advance IMC-2 into Phase 2b research. For more information, please visit Forward-Looking Statements: Statements in this press release contain 'forward-looking statements,' within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'suggest,' 'target,' 'aim,' 'should,' "will,' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to Dogwood's product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled 'Risk Factors' in the Annual Report on Form 10-K for the year ended December 31, 2024, which has been filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law. Investor Relations: CORE IR(516) 222-2560IR@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
16-05-2025
- Yahoo
‘Gastric bypass pill' causes weight loss without side effects: Study
(NewsNation) — A daily pill could give patients the weight-loss benefits of gastric bypass surgery or drugs like Ozempic — with none of the negative side effects, according to a recent clinical trial. Researchers say the SYNT-101 pill, developed by Boston-based Syntis Bio, mimics the effects of gastric bypass surgery while preserving muscle mass better than GLP-1 drugs like Ozempic, Wegovy and Mounjaro. The pill forms a film on the small intestine that redirects nutrient exposure to the lower intestine and gives patients a feeling of fullness — effectively mimicking gastric bypass surgery, which reroutes a person's intestines. The coating lasts up to 24 hours before it's expelled from the body. Who is eligible for weight loss medication? 'A lot remains to be seen with these medications, but the studies that we've seen so far look really promising,' said Dr. Jessica Duncan, an obesity medicine physician. The pill led to consistent weight loss and maintained lean muscle mass in rodent trials, and the first human study confirmed the pill formed a film and was safely cleared from the body within a day. 'These data further validate the potential of SYNT-101 as a convenient once-daily oral alternative or complement to GLP-1 drugs, which often involve substantial costs, severe side effects such as muscle loss and long-term maintenance issues despite high efficacy rates,' said Rahul Dhanda, CEO of Syntis, in a statement. Are weight loss drugs safe? Learn some of the side effects The study has limitations. The human trial only examined effects on nine patients who took one dose. Patients included seven women and two men between 24 and 53 who were not considered obese. 'So in that small group of people, they had no side effects, no serious or adverse events, and they didn't have any gastrointestinal side effects,' Duncan said. 'But with nine people, it's really hard to tell.' Duncan said the pill's safety profile will be developed in upcoming clinical trials. She told NewsNation that, whether weight loss is coming from a pill, surgery or injection, it's important to preserve muscle mass and eat well. 'Medications are super helpful for correcting the biological causes of obesity, but you have to make those lifestyle changes as well,' Duncan added. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.